

March 20, 2025

Representative Kendra Moore

P.O. Box 1151

Lincoln, Arkansas 72744

Re: HB 1801 – Support for Expanding Access to Compounded Medications

Representative Moore,

On behalf of the Alliance for Pharmacy Compounding, we appreciate the opportunity to express our support for HB 1801, which seeks to authorize outsourcing facilities of legend drugs and controlled substances to provide compounded products to certain healthcare entities within Arkansas.

APC represents a broad coalition of pharmacists, compounding professionals, and industry partners dedicated to ensuring patient access to high-quality, customized medications. As the voice of pharmacy compounding, we advocate for policies that balance regulatory oversight with the critical need for access to compounded therapies, particularly in cases where commercially available options are limited or unavailable.

HB 1801 represents an important step in ensuring that Arkansas patients have timely access to necessary compounded medications. By allowing 503B outsourcing facilities to distribute compounded products directly to licensed healthcare entities, including pharmacies for dispensing directly to patients, this legislation enhances continuity of care, supports patient safety, and helps address ongoing drug shortages that may affect treatment options for vulnerable populations.

We commend you for recognizing the importance of this issue and taking proactive steps to support both pharmacists and healthcare providers in their efforts to deliver quality patient care. APC stands ready to collaborate with policymakers, regulatory bodies, and industry stakeholders to ensure the successful implementation of this legislation and to provide any additional insights as needed.

Should you have any questions or require further information, please do not hesitate to contact me at scott@a4pc.org.

Sincerely,



Scott Brunner, CAE
Chief Executive Officer

The Alliance for Pharmacy Compounding is the voice for pharmacy compounding, representing more than 600 compounding small businesses – including compounding pharmacists and technicians in both 503A and 503B settings – as well as prescribers, educators, researchers, and suppliers.